
Experts in gastroenterology discuss treatment selection in special situations of CD, such as age, women considering pregnancy, and extra-intestinal manifestations.

Experts in gastroenterology discuss treatment selection in special situations of CD, such as age, women considering pregnancy, and extra-intestinal manifestations.

Remo Panaccione, MD, FRCPC, provides an overview of the newest oral therapy approved for CD, upadacitinib.

David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment.

David Rubin, MD, reviews the use of IL-12 and IL-23 inhibitors in the treatment of CD, highlighting ustekinumab and risankizumab for first-line therapy and beyond.

Experts in gastroenterology provide an overview of anti-TNF (tumor necrosis factor) and anti-integrin therapies in treatment of CD.

Sara Horst, MD, MPH, and Miguel Regueiro, MD, comment on the changing treatment landscape of CD, as well as share approaches to communicate with patients about starting biologic treatment early on in CD.

Experts in gastroenterology share approaches to engaging patients in achieving treatment targets beyond symptom control.

Experts continue the discussion on treat-to-target in CD, highlighting monitoring treatment response.

Miguel Regueiro, MD, and David Rubin, MD, review the treat-to-target strategy in relation to CD management, and how treat-to-target moves beyond symptom control.

Sara Horst, MD, MPH, comments on early introduction of biologics in the treatment of CD, highlighting her approach to initiating conversations with patients about advanced therapy.

Experts discuss the idea that, while symptoms of Crohn’s disease (CD) contribute to a patient’s quality of life, symptom control alone is not sufficient and the focus should be modifying the disease process.

Dr Sara Horst leads the discussion on the commonly followed treatment approach in the community for moderate to severe Crohn's Disease (CD) and highlights the factors that should guide treatment choices.

David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long summarize their discussion of Inflammatory Bowel Disease (IBD) and discuss prospective advances in treatment options.

Experts discuss the recent use of biosimilars like inolimomab as treatment for ulcerative colitis (UC).

Experts offer clinical advice on therapy sequencing of Janus kinase (JAK) inhibitors for ulcerative colitis (UC) and when surgery may be appropriate.

Experts discuss how they utilize Janus kinase (JAK) inhibitors for patients with ulcerative colitis (UC).

Millie Long, David Hudesman, MD, Maia Kayal, MD, and Miguel Regueiro, MD, discuss treatment strategies for ulcerative colitis (UC) utilizing ustekinumab.

Miguel Regueiro, MD, discusses the role of ozanimod as a treatment option for ulcerative colitis (UC).

Anita Afzali, MD, discusses treatment approaches to ulcerative colitis (UC) and how they may differ from Crohn’s Disease (CD).

Experts summarize their clinical strategies for monitoring and treating patients with Crohn’s Disease (CD).

Millie Long, Miguel Regueiro, MD, Maia Kayal, MD, Anita Afzali, MD, and David Hudesman, MD, offer clinical strategies for optimizing treatments for Crohn’s Disease (CD) patients.

Miguel Regueiro, MD, offers his clinical advice on second-line therapies for patients with Crohn’s Disease (CD).

Anita Afzali, MD, David Hudesman, MD, and Maia Kayal, MD, discuss how extra intestinal manifestations (EIM) affect therapy strategies for Crohn’s Disease (CD) patients.

Millie Long discusses treatment considerations for Crohn’s Disease (CD) patients who are planning for pregnancy.

Experts discuss the results of a five-year efficacy and safety trial of ustekinumab for treatment of Crohn’s Disease (CD).

Anita Afzali, MD, David Hudesman, MD, Millie Long, and Miguel Regueiro, MD, discuss Vedolizumab and Risankizumab as treatments for Crohn’s Disease (CD).

David Hudesman, MD, Miguel Regueiro, MD, and Maia Kayal, MD, offer first line treatment strategies for patients with Crohn’s Disease (CD).

Experts discuss how to care for Inflammatory Bowel Disease (IBD) patients who are not responding to treatment.

Experts discuss treatment options for patients with Inflammatory Bowel Disease (IBD) and clinical factors to consider.

David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long discuss the current treatment landscape for Inflammatory Bowel Disease (IBD).

January 22nd 2024

January 11th 2023

December 14th 2022

January 29th 2024

December 21st 2022